Výsledky vyhledávání

Akademický článek

Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study.

Autor: Sarah J E Barry, Eleanor Dinnett, Sharon Kean, Allan Gaw, Ian Ford

Publikováno v: PLoS ONE, Vol 8, Iss 9, p e75379 (2013)

Routinely collected electronic patient records are already widely used in epidemiological research. In this work we investigated the potential for using them to identify endpoints in clinical trials.The events recorded in the West of Scotland Coronar

Externí odkaz: https://doaj.org/article/d760abb0dbaa4ed4927772b5b05181b0

Zobrazit plný text záznamu

Accuracy of patient recall of preoperative symptom severity (angina and breathlessness) at one year following aorta-coronary artery bypass grafting

Autor: Grace M. Lindsay, Eric E Brodie, Allan Gaw, Philip R. Belcher, Kate A Niven

Publikováno v: Journal of Clinical Nursing. 18:418-425

Aim and objective. The accuracy with which patients recall their cardiac symptoms prior to aorta-coronary artery bypass grafting is assessed approximately one year after surgery together with patient-related factors potentially influencing accuracy o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a986545926f93315009653e1e501d680
https://doi.org/10.1111/j.1365-2702.2008.02559.x

Zobrazit plný text záznamu

Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study

Autor: Michael B. Murphy, Peter W. Macfarlane, Brendan M. Buckley, A.J.M. de Craen, Allan Gaw, Edward L.E.M. Bollen, Johan Wouter Jukema, David J. Stott, Chris J. Packard, J. Shepherd, Stella Trompet, P.E. Slagboom, Gerard-Jan Blauw, Ian Ford, Rudi G. J. Westendorp

Publikováno v: Experimental Gerontology. 43:801-805

Inflammation plays a prominent role in the development of atherosclerosis, which is the most important risk factor for vascular events. Lymphotoxin-alpha (LTA) is a pro-inflammatory cytokine and is found to be expressed in atherosclerotic lesions. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aa0af81515ddaf463b6dc2ef7529d8e
https://doi.org/10.1016/j.exger.2008.04.006

Zobrazit plný text záznamu

Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk

Autor: Luis Miguel Blanco-Colio, Gian Franco Gensini, Jesús Egido, Csaba Farsang, Allan Gaw, Lawrence A. Leiter, José Luis Martín-Ventura, Eduardo de Teresa, Anatoly Langer, Xavier Masramon, Carmen Gomez-Guerrero

Publikováno v: European Journal of Pharmacology. 586:259-265

Adiponectin can suppress atherogenesis by inhibiting the adherence of monocytes, reducing their phagocytic activity, and suppressing the accumulation of modified lipoproteins in the vascular wall. Contradictory data have been reported about the effec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f141ca579a339964c4606b82197cbd75
https://doi.org/10.1016/j.ejphar.2008.02.042

Zobrazit plný text záznamu

Association Between Apolipoprotein E4 and Cognitive Decline in Elderly Adults

Publikováno v: Journal of the American Geriatrics Society. 55:1777-1785

OBJECTIVE: To determine the inﬂuence of apolipoproteinEoncognitivedeclineinacohortofelderlymenandwomen.DESIGN: Prospective study.SETTING: Scotland, Ireland, and the Netherlands.PARTICIPANTS: Five thousand eight hundred four subjectsaged70to 82fromt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::067b77b4b6daf22bb4a967f4ae295341
https://doi.org/10.1111/j.1532-5415.2007.01415.x

Zobrazit plný text záznamu

A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study

Autor: Allan Gaw, Vasilios G. Athyros, C. Farsang

Publikováno v: Current Medical Research and Opinion. 23:1945-1956

ACTFAST-2 was designed to match the starting dose of a statin to the baseline low density lipoprotein-cholesterol (LDL-C) value, to allow high-risk European subjects to achieve LDL-C targets within 12 weeks with the initial dose or one up-titration.T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54592aaf2f741caf64bd19a2982f2ca3
https://doi.org/10.1185/030079907x223242

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání